We collected 103 clinical Enterococcus faecium isolates from across Canada, performed standard broth microdilution susceptibility testing, and compared these results with results from the MicroScan Pos MIC Type 6 panel (Baxter Health Care Corp., West Sacramento, Calif.) and the AMS-Vitek Gram-Positive Susceptibility card (Vitek Inc., St. Louis, Mo.). High-level aminoglycoside resistance to gentamicin and streptomycin was detected by a single-concentration agar method with 1,000 ,ug of each aminoglycoside per ml. In addition, we tested the effect of the lower calcium content in broth media as recommended in National Committee for Clinical Laboratory Standards (NCCLS) guideline M7-A2 on the activity of the highly calcium-dependent agent daptomycin. Of the 103 E. faecium isolates, there were 4 and 30 isolates with high-level gentamicin resistance (HLGR) and high-level streptomycin resistance (HLSR), respectively. An additional 39 (37 with HLGR and 36 with HLSR) E. faecium isolates were tested by both the MicroScan and the AMS-Vitek systems. The AMS-Vitek card demonstrated sensitivities of 95 and 82% for detecting HLGR strains and HLSR strains, respectively. The MicroScan panel demonstrated improved sensitivities for detecting HLGR (42 to 97%) and HLSR (64 to 84%) when readings were performed manually instead of being generated automatically. Ampicillin resistance (MIC, .16 ,ug/ml) was detected in 23 of the 103 E. faecium isolates. Only 14 and 20 of these were detected by the MicroScan panels and AMS-Vitek cards, respectively. P-Lactamase activity was not detected in any isolates. The lower calcium content in broth media recommended by NCCLS guideline M7-A2 markedly reduced the in vitro activity of daptomycin against Enterococcus spp.
erately resistant to aminoglycosides (MICs, 2 to 16 ,ug/ml). Nevertheless, enterococcal infections can be treated effectively with synergistic combinations of a cell wall-active agent plus an aminoglycoside (15, 27, 29) . When enterococcal strains acquire aminoglycoside-inactivating enzymes, high-level aminoglycoside resistance (HLAR) (MICs, .2,000 jig/ml) develops, and the synergism with a cell wall agent is lost (8, 14) . High-level gentamicin resistance (HLGR) has been reported among clinical isolates of both Enterococcus faecalis and Enterococcus faecium (3, 9, 13, 28) . In addition, ,-lactamase-producing E. faecalis isolates (17, 20) and vancomycin-resistant enterococci (11, 24) have been reported. Non-,-lactamase-producing strains of enterococci that are highly resistant to ampicillin have also been reported (1, 22) .
E. faecalis and E. faecium are the predominant enterococcal species associated with clinical infections in humans. In general, E. faecium strains are less susceptible to the ,-lactams and aminoglycosides than are E. faecalis strains, and E. faecium strains are often more refractory to the synergistic effect of the antibiotic combination. Since few studies have specifically focused on the susceptibility patterns of a large number of clinical isolates of E. faecium, we carried out in vitro susceptibility testing of a large number of isolates * Corresponding author.
obtained from across Canada against standard and new antimicrobial agents and determined the prevalence of HLAR. We compared these results with the susceptibility test results generated by the MicroScan Pos MIC Type 6 panel (Baxter Health Care Corp., West Sacramento, Calif.) and the AMS-Vitek Gram-Positive Susceptibility card (Vitek Inc., St. Louis, Mo.). In addition, we determined the effect of the National Committee for Clinical Standards (NCCLS) guideline M7-A2 (19) calcium concentration recommendations on the in vitro activity of daptomycin, which has in vitro antimicrobial activity that is highly calcium dependent (2, 6, 10, 25 For the detection of HLAR, single-concentration agar screen plates were prepared with brain heart infusion agar (Oxoid, Basingstoke, England) with 1,000 pLg of gentamicin and 1,000 ,ug of streptomycin per ml (7, 16 "As in M7-A (previous NCCLS guidelines).
As in M7-A2 (current NCCLS guidelines).
30). The MICs for E. faecalis are severalfold lower than those for E. faecium, in keeping with the more-pronounced intrinsic resistance of E. faecium. Since the first report of plasmid-mediated HLGR in strains of E. faecalis (9), the frequency of HLGR has increased to between 4.5 and 55% (13, 28) . Although reports of HLAR in E. faecium are few (1, 3), we found 3.9% of 103 clinical isolates of E. faecium to have HLGR, 29% to have HLSR, and 2.9% to have highlevel resistance to both aminoglycosides. Since the prevalence of HLAR appears to be low among clinical E. faecium isolates collected from across Canada, we selected additional E. faecium isolates with known HLAR to better evaluate the accuracy of the MicroScan panels and AMSVitek cards to detect HLAR. We used brain heart infusion agar screen plates containing 1,000 ,ug of gentamicin or streptomycin per ml. Previous studies have incorporated 2,000 ,ug of streptomycin per ml for testing; as in our previous study with E. faecalis (7), we found that results obtained with either 1,000 or 2,000 ,ug of streptomycin per ml were consistent and concordant when E. faecium was tested (data not shown 16 and 32 [Lg/ml but were able to detect most isolates with MICs .64 ,ug/ml. There was no difference in the number of ampicillin-resistant strains detected by manual and automated MicroScan readings (data not shown). The AMS-Vitek system is superior to the MicroScan system in detecting both lower and higher levels of ampicillin resistance among E. faecium isolates but erred in calling six isolates resistant when they were susceptible. Although this resulted in minor errors, difficulties in interpretation appear to center near the recommended interpretive breakpoint of the system. Most laboratories do not test beyond the concentration recommended by the NCCLS guideline. Further studies are needed to determine at what level ampicillin resistance reliably predicts loss of synergy with an aminoglycoside and whether current commercial susceptibility tests are adequate in detecting resistance at such a level (1, 22) . Resistance to vancomycin and teicoplanin has been described (12) but was not detected in this study.
We found that lowering the calcium content from 50 to 25 mg/liter resulted in a significantly greater MIC of daptomycin for enterococci. Although this phenomenon is reported in other organisms, it is most evident in enterococci (2, 6, 10, 25) . The critical calcium content in broth for maximal daptomycin activity was not determined. Broth microdilution susceptibility testing for daptomycin can lead to erroneous interpretations as either susceptible or resistant, depending on the concentration of calcium used. Reporting an organism as resistant to daptomycin when daptomycin may be of clinical value may be deleterious. The clinical significance of these observations needs to be clarified and correlated with clinical treatment studies. A consensus regarding acceptable MIC breakpoints for interpretation of microdilution broth susceptibility testing is necessary in light of these results.
Antimicrobial resistance among isolates of E. faecium has made treatment of infection due to these organisms an ongoing challenge. Routine susceptibility testing for enterococci should include determination of susceptibility to ampicillin and vancomycin in addition to screening for HLAR. At present, the MicroScan Pos MIC Type 6 panel and the AMS-Vitek Gram-Positive Susceptibility card are not accurate for these purposes, and alternative testing methods should be used.
